



ZOOM ON: Microbiota and cancer

- NEWS: A new imodi-cancer.org website!
- IMODI around the world: Posters
- FOCUS on: BIOFORTIS innovation services



ZOOM

Microbiota and cancer : A clinical research protocol to study gut microbiota of cancer patients



The national project IMODI, aims to develop new patient-derived tumor graft (PDX) models that will be used for speed up innovative therapeutic approach development. Well characterized PDX models that come from 9 types of human cancer represent a suitable tool for preclinical evaluation of novel therapeutic strategies in cancer.

It is now well established that, besides genetic features, one major host determinant in human health is the gut microbiota. These billions of microorganisms that colonize our gut contribute to human health but microbiota imbalance could be involved in cancer development.

As one of the original partners in this consortium, Biofortis Mérieux NutriSciences brings its experience in clinical trial management and its scientific knowledge in microbiota research.

The first objective is to coordinate the clinical study from 7 French clinical centers, for the recruitment of patients presenting several types of cancer: breast, ovary, liver and prostate. A stool and blood biobank associated with patient's medical information will be generated, clinically characterized and standardized for biospecimen provider.

The second role is to (...) [Read more on the website](#)

 [More about](#)

NEWS



A new website for IMODI

IMODI launches its new website! Redesigned, more ergonomic, more complete and more comprehensive, IMODI website is a showcase project. It presents its researches, discoveries, partners and sponsors. You will now find a real «News & Events» page regularly updated and a «Products and Services» section available to the scientific community.

Get connected! IMODI is now present on the Twitter and LinkedIn networks. Follow us on [@IMODI_Cancer](https://twitter.com/IMODI_Cancer) and www.linkedin.com/company/imodi-cancer

 [More about](#)

IMODI AROUND THE WORLD



1st results presented at the AACR & Probiota Meetings in February and April 2016

IMODI partners presented the first results from their research projects to **PROBIOTA** conference (2-4 February, Amsterdam) and **AACR Annual Meeting** (April 16-20, New Orleans).

- [Innovative and Predictive Models against cancer: an IMODI integrative approach](#)
- [Pharmacological Testing of Chemotherapy in PDX Models: Impact on Gut Microbiota](#)

 [More about](#)

FOCUS




Biofortis innovation services

Biofortis, a subsidiary of Mérieux NutriSciences, part of the Mérieux Group, is a leading global research organization serving innovation in food, nutrition and health. With locations in Europe & North America, Biofortis offers complementary, differentiating and innovative services including pre-clinical and clinical assessments, Central Laboratory analysis and microbiota-related research for large and medium companies mainly in the nutrition, pharmaceutical and biotechnology areas.

Our main activity is to support our clients in their quest for innovative market leading products by generating scientific evidence.

Biofortis, as a leading Contract Research Organization, is specialized in designing and running clinical research projects in several health areas: cardiovascular, metabolism, immunity, cognitive function, nutrition and especially in gut health, with a dedicated microbiome analytical service.



Biofortis combines an experienced and GCP-trained staff (clinical, data management, biostatistics, bioinformatics...) with a strong network of scientists and several collaborations with key opinion leaders of international reputation.

Based on its own Clinical investigation Center and its accredited Central Laboratory, Biofortis offers a global and a continuous solution to support its offer in Clinical Research from study design to scientific publications. To anticipate tomorrow's healthcare challenges, Biofortis has set up a metagenomic platform to bring insights on the impact of a nutraceutical product, a functional food or a treatment on the microbiome.

Thanks to that, our engagement is to provide our clients the latest development in microbiome research that can value their product development.

More about



Model and treat the diversity of cancers

- 2013/01/01:** Creation of the consortium
- 2013/09/01:** Signature of the consortium agreement
- 2015/10/01:** Signature of the 1st licence agreement
- 7 years:** duration of the 1st R&D phase
- 150** Researchers
- 6** SMEs
- 4** pharmaceutical industries
- 8** Academic institutions

What about IMODI

www.imodi-cancer.org

The french IMODI (Innovative MODEls Initiative) consortium is dedicated to the development, the characterization and the commercialization of new preclinical models in oncology.

IMODI is a public-private consortium of 18 partners pooling their resources for the development of more valuable models of cancer in order to decrease the attrition rate of clinical development of novel anti-cancer agents.

Science and technology developments:



Developing PDX models and cellular assays



Modelling the human tumour microenvironment in mice



Studying the relationship between microbiota and cancer

IMODI's partners

